5 mg/ml poudre pour solution à diluer pour perfusion

DRUG3 trials

Sponsors

F. Hoffmann-La Roche AG, Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau, BeOne Medicines AG

Conditions

Chronic Lymphocytic Leukemia (CLL)Chronic lymphotic leukemia and Small Lymphocytic lymphomaRefractary or relapse Hodgkin T CD30+ lymphomaRefractary or relapse non-Hodgkin T CD30+ lymphoma.

Phase 1

Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressing an anti-CD30-chimeric antigen receptor with 4-1-BB and CD3z costimulatory sequences in patients with Classical Hodgkin lymphoma and non-Hodgkin CD30+ T cell lymphoma.

Not yet recruitingCTIS2024-515624-36-00

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant PauRefractary or relapse Hodgkin T CD30+ lymphoma, Refractary or relapse non-Hodgkin T CD30+ lymphoma.

Target: 40Updated: 2025-08-29

Phase 3

A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP53 Mutation

CompletedCTIS2023-504036-17-00

F. Hoffmann-La Roche AGChronic Lymphocytic Leukemia (CLL)

Start: 2020-05-07End: 2025-03-18Target: 121Updated: 2025-04-17

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

RecruitingCTIS2024-518893-15-00

BeOne Medicines AGChronic lymphotic leukemia and Small Lymphocytic lymphoma

Start: 2025-07-29Target: 56Updated: 2026-01-14